Integral Health Asset Management LLC Raises Stock Position in uniQure (NASDAQ:QURE)

Integral Health Asset Management LLC boosted its holdings in uniQure (NASDAQ:QURE) by 175.0% in the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 1,100,000 shares of the biotechnology company’s stock after buying an additional 700,000 shares during the period. uniQure accounts for approximately 1.7% of Integral Health Asset Management LLC’s holdings, making the stock its 20th biggest position. Integral Health Asset Management LLC owned about 2.26% of uniQure worth $19,426,000 at the end of the most recent quarter.

A number of other institutional investors have also bought and sold shares of the business. Balyasny Asset Management L.P. increased its stake in uniQure by 53.8% in the 4th quarter. Balyasny Asset Management L.P. now owns 359,173 shares of the biotechnology company’s stock worth $6,343,000 after buying an additional 125,682 shares in the last quarter. Bellevue Group AG purchased a new position in shares of uniQure during the fourth quarter valued at about $397,000. BNP Paribas Financial Markets grew its position in shares of uniQure by 9.6% during the fourth quarter. BNP Paribas Financial Markets now owns 468,357 shares of the biotechnology company’s stock valued at $8,271,000 after purchasing an additional 41,166 shares in the last quarter. Boxer Capital Management LLC purchased a new position in shares of uniQure during the fourth quarter valued at about $13,245,000. Finally, Schonfeld Strategic Advisors LLC purchased a new position in shares of uniQure during the fourth quarter valued at about $9,473,000. Hedge funds and other institutional investors own 78.83% of the company’s stock.

uniQure Stock Performance

Shares of NASDAQ:QURE opened at $12.78 on Monday. The company has a market capitalization of $700.04 million, a price-to-earnings ratio of -2.58 and a beta of 0.10. uniQure has a 52 week low of $3.73 and a 52 week high of $19.18. The company has a quick ratio of 6.51, a current ratio of 6.51 and a debt-to-equity ratio of 0.92. The firm has a 50 day moving average of $12.22 and a 200 day moving average of $12.13.

uniQure (NASDAQ:QURE) last issued its quarterly earnings results on Friday, May 9th. The biotechnology company reported ($0.82) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.07) by $0.25. The business had revenue of $1.57 million for the quarter, compared to the consensus estimate of $5.93 million. uniQure had a negative return on equity of 188.82% and a negative net margin of 837.80%. On average, sell-side analysts predict that uniQure will post -3.75 earnings per share for the current fiscal year.

Insider Transactions at uniQure

In related news, CEO Matthew C. Kapusta sold 26,727 shares of the company’s stock in a transaction on Tuesday, February 25th. The stock was sold at an average price of $10.70, for a total value of $285,978.90. Following the transaction, the chief executive officer now directly owns 571,188 shares of the company’s stock, valued at $6,111,711.60. This represents a 4.47% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Christian Klemt sold 2,916 shares of the company’s stock in a transaction on Thursday, February 27th. The shares were sold at an average price of $11.32, for a total value of $33,009.12. Following the completion of the transaction, the chief financial officer now directly owns 155,168 shares in the company, valued at approximately $1,756,501.76. The trade was a 1.84% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 90,830 shares of company stock valued at $961,401. Corporate insiders own 4.74% of the company’s stock.

Wall Street Analysts Forecast Growth

QURE has been the subject of several recent research reports. Royal Bank of Canada reiterated an “outperform” rating and issued a $24.00 price target on shares of uniQure in a research report on Tuesday, January 21st. Chardan Capital reissued a “buy” rating and issued a $38.00 price objective on shares of uniQure in a research note on Tuesday, May 6th. HC Wainwright reissued a “buy” rating and issued a $70.00 price objective on shares of uniQure in a research note on Monday, April 21st. Wells Fargo & Company decreased their price objective on shares of uniQure from $35.00 to $30.00 and set an “equal weight” rating for the company in a research note on Friday, February 28th. Finally, StockNews.com raised shares of uniQure to a “sell” rating in a research note on Tuesday, March 11th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, uniQure has an average rating of “Moderate Buy” and an average price target of $38.80.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.